JP2023518439A5 - - Google Patents

Info

Publication number
JP2023518439A5
JP2023518439A5 JP2022556142A JP2022556142A JP2023518439A5 JP 2023518439 A5 JP2023518439 A5 JP 2023518439A5 JP 2022556142 A JP2022556142 A JP 2022556142A JP 2022556142 A JP2022556142 A JP 2022556142A JP 2023518439 A5 JP2023518439 A5 JP 2023518439A5
Authority
JP
Japan
Prior art keywords
nucleotides
dsrna
antisense
chain
antisense strand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022556142A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518439A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/022688 external-priority patent/WO2021188626A1/en
Publication of JP2023518439A publication Critical patent/JP2023518439A/ja
Publication of JP2023518439A5 publication Critical patent/JP2023518439A5/ja
Priority to JP2026025899A priority Critical patent/JP2026106461A/ja
Pending legal-status Critical Current

Links

JP2022556142A 2020-03-18 2021-03-17 Mapt調節のためのオリゴヌクレオチド Pending JP2023518439A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026025899A JP2026106461A (ja) 2020-03-18 2026-02-20 Mapt調節のためのオリゴヌクレオチド

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062991405P 2020-03-18 2020-03-18
US62/991,405 2020-03-18
US202063071106P 2020-08-27 2020-08-27
US63/071,106 2020-08-27
PCT/US2021/022688 WO2021188626A1 (en) 2020-03-18 2021-03-17 Oligonucleotides for mapt modulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026025899A Division JP2026106461A (ja) 2020-03-18 2026-02-20 Mapt調節のためのオリゴヌクレオチド

Publications (2)

Publication Number Publication Date
JP2023518439A JP2023518439A (ja) 2023-05-01
JP2023518439A5 true JP2023518439A5 (cg-RX-API-DMAC7.html) 2024-03-28

Family

ID=77768304

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022556142A Pending JP2023518439A (ja) 2020-03-18 2021-03-17 Mapt調節のためのオリゴヌクレオチド
JP2026025899A Pending JP2026106461A (ja) 2020-03-18 2026-02-20 Mapt調節のためのオリゴヌクレオチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026025899A Pending JP2026106461A (ja) 2020-03-18 2026-02-20 Mapt調節のためのオリゴヌクレオチド

Country Status (9)

Country Link
US (2) US20210363523A1 (cg-RX-API-DMAC7.html)
EP (1) EP4121537A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023518439A (cg-RX-API-DMAC7.html)
KR (1) KR20230004448A (cg-RX-API-DMAC7.html)
CN (1) CN115552006A (cg-RX-API-DMAC7.html)
AU (1) AU2021238319A1 (cg-RX-API-DMAC7.html)
CA (1) CA3171246A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022011516A (cg-RX-API-DMAC7.html)
WO (1) WO2021188626A1 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3929293A3 (en) 2015-04-03 2022-03-16 University Of Massachusetts Fully stabilized asymmetric sirna
WO2017030973A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
WO2018237245A1 (en) 2017-06-23 2018-12-27 University Of Massachusetts TWO TAIL SELF-ADMINISTRATION SIRNA AND ASSOCIATED METHODS
BR112021002440A2 (pt) 2018-08-10 2021-05-04 University Of Massachusetts oligonucleotídeos modificados visando snps
WO2020041769A1 (en) 2018-08-23 2020-02-27 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
CN113614232A (zh) 2019-01-18 2021-11-05 马萨诸塞大学 动态药代动力学修饰锚
KR20220047989A (ko) 2019-08-09 2022-04-19 유니버시티 오브 매사추세츠 Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
JP2023521604A (ja) * 2020-03-30 2023-05-25 アルナイラム ファーマシューティカルズ, インコーポレイテッド 微小管関連タンパク質タウ(MAPT)iRNA剤組成物およびその使用方法
CA3174079A1 (en) 2020-05-26 2021-12-02 Anastasia Khvorova Synthetic oligonucleotides having regions of block and cluster modifications
KR20240067943A (ko) * 2021-09-24 2024-05-17 알닐람 파마슈티칼스 인코포레이티드 미소관 연관 단백질 타우(MAPT) iRNA 제제 조성물 및 이의 사용 방법
US20250340872A1 (en) * 2021-10-07 2025-11-06 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing tau expression
MX2024007056A (es) * 2021-12-13 2024-06-24 Lilly Co Eli Agentes de interferencia de arn de mapt.
US20250171777A1 (en) * 2022-02-11 2025-05-29 Alnylam Pharmaceuticals, Inc. Microtubule Associated Protein Tau (MAPT) iRNA Agent Compositions and Methods of Use Thereof
US20230392146A1 (en) * 2022-03-11 2023-12-07 University Of Massachusetts Oligonucleotides for app modulation
WO2023193004A2 (en) * 2022-04-01 2023-10-05 Triplet Therapeutics, Inc. Methods for the treatment of neurodegenerative disorders
CA3247389A1 (en) * 2022-05-12 2023-11-16 Dicerna Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF MAPT
CA3246379A1 (en) * 2022-05-13 2023-11-16 Julius-Maximilians-Universität Würzburg METHOD AND MOLECULES FOR REDUCING AXONAL TAU PROTEIN ACCUMULATION BY BLOCKING HNRNP R-MEDICATED MRNA TRANSPORT FOR THE TREATMENT OF ALZHEIMER'S DISEASE
WO2024073618A2 (en) * 2022-09-29 2024-04-04 Atalanta Therapeutics, Inc. Sirna compositions and methods targeting microtubule associated protein tau nucleic acids
WO2024145474A2 (en) * 2022-12-29 2024-07-04 Voyager Therapeutics, Inc. Compositions and methods for regulating mapt
WO2024201423A2 (en) * 2023-03-30 2024-10-03 Biorchestra Co., Ltd. Microtubule-associated protein tau targeting sirnas and uses thereof
EP4698652A2 (en) * 2023-04-20 2026-02-25 Adarx Pharmaceuticals, Inc. Mapt-modulating compositions and methods of use thereof
KR20260046111A (ko) * 2023-08-01 2026-04-06 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 MAPT를 표적으로 하는 dsRNA 및 이의 의약적 용도
KR20260085142A (ko) * 2023-10-11 2026-06-08 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. 미세소관 관련 단백질 tau(mapt)의 발현을 억제하기 위한 조성물 및 방법
WO2025212467A1 (en) * 2024-03-31 2025-10-09 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of microtubule associated protein tau (mapt), compositions thereof, and methods of use
WO2025233849A2 (en) * 2024-05-07 2025-11-13 Janssen Pharmaceutica Nv MAPT siRNA AND USES THEREOF
US20260167963A1 (en) * 2024-08-29 2026-06-18 Synerk Inc. Compounds, Compositions and Methods for Reducing MAPT (TAU) Expression
WO2026090357A1 (en) * 2024-10-24 2026-04-30 Adarx Pharmaceuticals, Inc. Mapt-modulating oligonucleotides for treating central nervous system diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050255086A1 (en) * 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
CA2585970A1 (en) * 2004-10-27 2006-05-04 Vanderbilt University Mammalian genes involved in infection
GB0605337D0 (en) * 2006-03-17 2006-04-26 Genomica Sau Treatment of CNS conditions
WO2008124066A1 (en) * 2007-04-05 2008-10-16 The J. David Gladstone Institutes Agents that reduce neuronal overexcitation
WO2010141511A2 (en) * 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
TWI702046B (zh) * 2013-07-19 2020-08-21 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
ES2820713T3 (es) * 2015-03-25 2021-04-22 Univ Degli Studi Di Trento Terapia mediada por ARN interferente para enfermedades neurodegenerativas
EP3929293A3 (en) * 2015-04-03 2022-03-16 University Of Massachusetts Fully stabilized asymmetric sirna
WO2017132669A1 (en) * 2016-01-31 2017-08-03 University Of Massachusetts Branched oligonucleotides
WO2020041769A1 (en) * 2018-08-23 2020-02-27 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
US20210115442A1 (en) * 2019-08-23 2021-04-22 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides

Similar Documents

Publication Publication Date Title
JP2023522701A5 (cg-RX-API-DMAC7.html)
JP2023518268A5 (cg-RX-API-DMAC7.html)
JP7554488B2 (ja) 血液脳関門通過型ヘテロ2本鎖核酸
AU2018205183B2 (en) Chiral control
JP7129702B2 (ja) オーバーハングを有する二本鎖核酸複合体
JP6985288B2 (ja) トリチル−モノ−GalNAc化合物とその利用
JP2021533804A5 (cg-RX-API-DMAC7.html)
JP2022528487A5 (cg-RX-API-DMAC7.html)
CN106795197B (zh) 改性寡核苷酸及其制备方法
JP2023550485A5 (cg-RX-API-DMAC7.html)
AU2022202011A1 (en) Short interfering nucleic acid (siNA) molecules containing a 2' internucleoside linkage
JP2022525208A5 (cg-RX-API-DMAC7.html)
KR20190044653A (ko) 4'-포스페이트 유사체 및 이를 포함하는 올리고뉴클레오타이드
JP2021533762A5 (cg-RX-API-DMAC7.html)
CN111448317B (zh) 包含二硫代磷酸酯核苷间键的缺口聚物寡核苷酸
TW202246502A (zh) 抑制中樞神經系統中的基因表現之組成物及方法
CN111448316B (zh) 新的硫代亚磷酰胺
JP2024523466A5 (cg-RX-API-DMAC7.html)
JP2026514403A (ja) オリゴヌクレオチド送達担体およびその使用方法
JP6882735B2 (ja) 構造強化されたmiRNA阻害剤S−TuD
TW202340462A (zh) 靶定中樞神經系統的寡樹突細胞之脂質結合物
WO2023081823A1 (en) Lipid conjugation for targeting astrocytes of the central nervous system
US20240287512A1 (en) Lipid conjugation for targeting neurons of the central nervous system
WO2021157730A1 (ja) 核酸医薬とその使用
CN111757936A (zh) 包含二硫代磷酸酯核苷间连接的寡核苷酸